Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, Share, Trends, Growth 2032
Duchenne Muscular Dystrophy (DMD) Therapeutics Market By Type (Small Molecules and Biologics), And By Region - Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2024 - 2032
| Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 2.13 Billion | USD 3.76 Billion | 6.50% | 2023 |
Table Of Content
- Chapter 1. Preface
- 1.1. Report Description and Scope
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology
- Chapter 2. Executive Summary
- 2.1. Duchenne Muscular Dystrophy (DMD) Therapeutics Market, 2016–2025 (USD Billion)
- 2.2. Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Snapshot
- Chapter 3. Duchenne Muscular Dystrophy (DMD) Therapeutics Market – Industry Analysis
- 3.1. Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Market Dynamics
- 3.2. Market Drivers
- 3.2.1. Growing funding for research and development activities
- 3.2.2. Technological advancements in diagnostic techniques
- 3.3. Restraints
- 3.3.1. Lack of awareness
- 3.3.2. Dearth of skilled researchers
- 3.4. Opportunities
- 3.4.1. Efforts taken by governments and non-government organizations to create awareness
- 3.5. Porter’s Five Forces Analysis
- 3.6. Market Attractiveness Analysis
- 3.6.1. Market attractiveness analysis By Type
- 3.6.2. Market attractiveness analysis by Region
- Chapter 4. Duchenne Muscular Dystrophy (DMD) Therapeutics Market– Competitive Landscape
- 4.1. Company market share analysis
- 4.1.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market: company market share, 2018
- 4.2. Strategic development
- 4.2.1. Acquisitions & mergers
- 4.2.2. New Product launches
- 4.2.3. Agreements, partnerships, cullaborations and joint ventures
- 4.2.4. Research and development and Regional expansion
- 4.3. Price trend analysis
- 4.1. Company market share analysis
- Chapter 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market –Type Analysis
- 5.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market overview: By Type
- 5.1.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market share, By Type,2018 and 2025
- 5.2. Small Mulecules
- 5.2.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Small Mulecules, 2016–2025 (USD Billion)
- 5.3. Biulogics
- 5.3.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Biulogics, 2016–2025 (USD Billion)
- 5.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market overview: By Type
- Chapter 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market - Regional Analysis
- 6.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market overview: by Region
- 6.1.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market share, by Region, 2018 and 2025
- 6.2. North America
- 6.2.1. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, 2016–2025 (USD Billion)
- 6.2.2. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
- 6.2.3. U.S.
- 6.2.3.1. U.S. Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
- 6.2.4. Rest of North America
- 6.2.4.1. Rest of North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
- 6.3. Europe
- 6.3.1. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, 2016–2025 (USD Billion)
- 6.3.2. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
- 6.3.3. UK
- 6.3.3.1. U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
- 6.3.4. France
- 6.3.4.1. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
- 6.3.5. Germany
- 6.3.5.1. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
- 6.3.6. Rest of Europe
- 6.3.6.1. Rest of Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
- 6.4. Asia Pacific
- 6.4.1. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market, 2016–2025 (USD Billion)
- 6.4.2. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
- 6.4.3. China
- 6.4.3.1. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
- 6.4.4. Japan
- 6.4.4.1. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
- 6.4.5. India
- 6.4.5.1. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
- 6.4.6. Rest of Asia Pacific
- 6.4.6.1. Rest of Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
- 6.5. Latin America
- 6.5.1. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, 2016–2025 (USD Billion)
- 6.5.2. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
- 6.5.3. Brazil
- 6.5.3.1. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
- 6.5.4. Rest of Latin America
- 6.5.4.1. Rest of Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
- 6.6. The Middle East and Africa
- 6.6.1. The Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market, 2016–2025 (USD Billion)
- 6.6.2. The Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
- 6.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market overview: by Region
- Chapter 7. Company Profiles
- 7.1. PTC Therapeutics Inc.
- 7.1.1. Overview
- 7.1.2. Financials
- 7.1.3. Type Portfolio
- 7.1.4. Business Strategy
- 7.1.5. Recent Developments
- 7.2. F. Hoffmann-La Roche Ltd.
- 7.2.1. Overview
- 7.2.2. Financials
- 7.2.3. Type Portfolio
- 7.2.4. Business Strategy
- 7.2.5. Recent Developments
- 7.3. Santhera Pharmaceuticals
- 7.3.1. Overview
- 7.3.2. Financials
- 7.3.3. Type Portfolio
- 7.3.4. Business Strategy
- 7.3.5. Recent Developments
- 7.4. Wave Life Sciences Ltd.
- 7.4.1. Overview
- 7.4.2. Financials
- 7.4.3. Type Portfolio
- 7.4.4. Business Strategy
- 7.4.5. Recent Developments
- 7.5. Wave Life Sciences Ltd.
- 7.5.1. Overview
- 7.5.2. Financials
- 7.5.3. Type Portfolio
- 7.5.4. Business Strategy
- 7.5.5. Recent Development
- 7.1. PTC Therapeutics Inc.
Table Of Figures
List of Figures
1. Market research process
2. Market research methodology
3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, 2016–2025 (USD Billion)
4. Porter’s Five Forces Analysis
5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market attractiveness, By Type
6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market attractiveness, By Region
7. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market share, By Type, 2018 and 2025
8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Small Molecules, 2016–2025 (USD Billion)
9. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Biologics,2016–2025 (USD Billion)
10. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market share, by Region, 2018and 2025
11. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, 2016–2025 (USD Billion)
12. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, 2016–2025 (USD Billion)
13. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market, 2016–2025 (USD Billion)
14. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, 2016–2025 (USD Billion)
15. The Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market, 2016–2025 (USD Billion)
Table Of Tables
List of Tables
1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Snapshot
2. Drivers of the Duchenne Muscular Dystrophy (DMD) Therapeutics Market: impact analysis
3. Restraints of the Duchenne Muscular Dystrophy (DMD) Therapeutics Market: impact analysis
4. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
5. U.S. Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
6. Rest of North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
7. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
8. U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
9. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
10. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
11. Rest of Europe Duchenne Muscular Dystrophy (DMD) Therapeutics revenue, By Type,2016–2025 (USD Billion)
12. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
13. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
14. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics revenue, By Type,2016–2025 (USD Billion)
15. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
16. Rest of Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
17. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
18. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
19. Rest of Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
20. The Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
Methodology
FrequentlyAsked Questions
Duchenne Muscular Dystrophy (DMD) therapies are medicines and medical interventions used to control and treat Duchenne Muscular Dystrophy, a severe type of muscular dystrophy that mostly affects boys. DMD is characterised by increasing muscle degeneration and weakening caused by dystrophin gene mutations, which are required for muscle fibre stability. The purpose of DMD therapy is to reduce disease progression, enhance quality of life, and increase life expectancy.
Several significant variables drive the growth of the Duchenne Muscular Dystrophy (DMD) therapies market, such as medical research advances, regulatory approvals, patient advocacy, and market dynamics.
The global duchenne muscular dystrophy (DMD) therapeutics market size was worth around USD 2.13 billion in 2023 and is predicted to grow to around USD 3.76 billion by 2032.
The global duchenne muscular dystrophy (DMD) therapeutics market a compound annual growth rate (CAGR) of roughly 6.50% between 2024 and 2032.
North America will be the leading region during the forecast period. High investment in research and development of Duchenne Muscular Dystrophy (DMD) therapeutics and presence of major manufacturers will boost the market growth in this region. Europe is expected to be the second major market. The key reasons are efforts taken by health agencies and advantageous reimbursement scenario.
PTC Therapeutics Inc., F. Hoffmann-La Roche Ltd., Santhera Pharmaceuticals, Wave Life Sciences Ltd., and Sarepta Therapeutics Inc. among others.
RelatedNews
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed